Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 and/or QL1706 in CLDN18.2+ solid tumors
NCT06446388Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QLS-31905, QL1706 in gastric cancer (GC), gastroesophageal junction cancer, biliary tract cancer (BTC), solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
QLS-31905QL1706
03
Conditions
gastric cancer (GC)gastroesophageal junction cancerbiliary tract cancer (BTC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06446388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06446388.